Much Ado About Something: Why There’s Excitement Behind Novel Mechanism of Action in Schizophrenia
CLINICAL CONVERSATIONS Later this month, the US Food and Drug Administration is scheduled to share results of the New Drug Application for Bristol Myers Squibb’s KarXT for the treatment of schizophrenia; the acceptance of the NDA was announced last year. …